Drugmakers Back US Probe into Germany’s New Drug Pricing Policies

Seven major pharmaceutical companies, together with industry groups PhRMA and BIO, have urged the German government to amend its recently introduced drug‑pricing reforms.

The coalition voiced support for the U.S. Trade Representative’s investigation, arguing that the new rules could restrict market access and dampen innovation.

They contend that price‑cap mechanisms tied to reimbursement create uncertainty for firms operating across Europe.

The appeal highlights growing tension between U.S. industry and European regulators as both seek to balance affordability with incentives for new medicines.